Biomea Fusion to Present at the 39^th Annual J.P. Morgan Healthcare Conference

REDWOOD CITY, Calif., Jan. 8, 2021 (BUSINESS WIRE) – Biomea Fusion, Inc., a precision oncology company dedicated to developing innovative medicines targeting genomically defined alterations in both hematologic and solid cancers, announced today that it will present at the upcoming virtual 39th Annual J.P. Morgan Healthcare Conference.  Founder and Chief Executive Officer, Thomas Butler, is scheduled to present on Monday, January 11, 2021 at 12:10 p.m. PT / 3:10 pm ET.

A live audio webcast of the presentation can be accessed at www.biomeafusion.com and will be available for 30 days following the presentation.

About Biomea Fusion
Biomea Fusion is a privately held precision medicine company with a mission to revolutionize drug development to create more effective therapies for cancer patients. The company was founded in 2017 by a team of experienced drug developers to build a platform of irreversible inhibitors.  Biomea Fusion has a development portfolio that targets specific gene alterations which occur in the DNA of patients that translate into key drivers of tumor growth.  It is Biomea’s goal to move these potentially breakthrough medicines swiftly through the development process and deliver highly impactful treatments for patients in need.  The lead program targets the protein-to-protein interaction between menin and the MLL complex for the treatment of various tumors.  This program is currently in IND enabling studies and is planned to enter the clinic in the second half of 2021.  For more information, please visit www.biomeafusion.com and follow us on LinkedIn.

Investor and Media Contact:
Ramses Erdtmann
Biomea Fusion, Inc.
(650) 980-9099
[email protected]